Asparaginase is essential to modern leukemia regimens, but hypersensitivity to E. coli-derived products forces a switch, and supply of the Erwinia alternative had been unreliable. Rylaze addressed both problems.
It depletes asparagine, an amino acid leukemia cells cannot synthesize but depend on to survive. Approved as a component of a chemotherapy regimen, it serves patients 1 month and older with acute lymphoblastic leukemia or lymphoblastic lymphoma who are allergic to E. coli-derived asparaginase.
As a recombinant product, Rylaze resolved the supply constraints that plagued the earlier Erwinia-derived enzyme, and it later added intravenous dosing alongside intramuscular administration. It holds orphan designation and remains the default option for hypersensitive patients.
